In Brief: Gull Laboratories
This article was originally published in The Gray Sheet
Gull Laboratories: Immunodiagnostics firm's majority shareholder Fresenius AG engages investment banking firm Wasserstein Perella & Co. to evaluate "various alternative" strategies for the unit, Gull states in an Oct. 23 release. Bad Homburg, Germany-based Fresenius, which holds a 62% stake in Gull, "has been approached by a number of firms expressing a potential interest in partnering or otherwise acquiring Gull," the firm states...
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.